Use of over-the-counter drugs in migraine: Issues in self-medication

CNS Drugs

Volumn 6, Issue 2, 1996, Pages 83-89

  Gilkey, Stephanie J ^a   Ramadan, Nabih M ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CAFFEINE; IBUPROFEN; KETOPROFEN; MAGNESIUM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEPPERMINT OIL; RIBOFLAVIN;

DRUG EFFICACY; DRUG USE; HUMAN; MIGRAINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SELF MEDICATION;

EID: 0029784727     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199606020-00001     Document Type: Review

References (54)

1. Isler H. Historical background. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. New York: Raven Press Ltd, 1993: 1-8
2. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1-96
3. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. JAMA 1992; 267: 64-9
4. Lipton LB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. Headache 1994; 34: 319-28
5. Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine headache and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993; 20: 131-7
6. Henry P, Michel P, Brochet B, et al. A nationwide survey of migraine in France: prevalence and clinical features in adults. Cephalalgia 1992; 12: 229-37
7. Rasmussen BK. Epidemiology of headache. Cephalalgia 1995; 15: 45-68
8. Gobel H, Petersen-Braun M, Soyka D. Headache in Germany. A nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society. In: Olesen J, editor. Frontiers in headache research. Vol. 4: Headache classification and epidemiology. New York: Raven Press Ltd, 1994: 225-61
9. Stewart WF, Shechter BA, Rasmussen BK. Migraine prevalence: a review of population-based studies. Neurology 1994; 44 Suppl. 4: S17-23
10. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993; 43 Suppl. 3: S6-10
11. Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol 1994; 34 Suppl. 2: 6-11
12. Edmeads J. The diagnosis and treatment of migraine: a clinician's view. Eur Neurol 1994; 34 Suppl. 2: 2-5
13. Lipton RB, Stewart WF. Medical consultation for migraine [abstract]. Neurology 1994; 44 Suppl. 2: A199
14. Stang PE, Osterhaus JT, Celentano DD. Migraine: patterns of healthcare use. Neurology 1994; 44 Suppl. 4: S47-55
15. Stewart WF, Lipton RB. Migraine awareness in US women [abstract]. Neurology 1992; 42 Suppl. 3: 262
16. Lipton RB, Stewart WF, Celentano DD, et al. Undiagnosed migraine headaches: a comparison of symptom-based and reported physician diagnosis. Arch Intern Med 1992; 152: 1273-8
17. Celentano DD, Stewart WF, Lipton RB, et al. Medication use and disability among migraineurs: a national probability sample survey. Headache 1992; 32: 223-8
18. Sheftell F. Educating headache patients: the role of The American Council for Headache Education (ACHE). Headache 1994; Suppl. 1: 27-8
19. Lipton RB, Newman LC, Solomon S. Over-the-counter medication and the treatment of migraine. Headache 1994; 34: 547-8
20. Solomon S. OTC analgesics in treating common primary headaches: a review of safety and efficacy. Headache 1994; Suppl. 1: 13-21
21. Diener HC. A review of current treatments for migraine. Eur Neurol 1994; 34 Suppl. 2: 18-25
22. Horn J. Pharmacology of over-the-counter analgesics used for the treatment of headache. Headache 1994; Suppl. 1: 6-9
23. Havanka-Kanniainen H. Treatment of acute migraine attack: ibuprofen and placebo compared. Headache 1989; 29: 507-9
24. Nestvold K, Kloster R, Partinen M, et al. Treatment of acute migraine attack: naproxen and placebo compared. Cephalalgia 1985; 5: 115-9
25. Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine. Cephalalgia 1985; 5: 5-10
26. Kangasniemi P, Kaaja R. Ketoprofen and ergotamine in acute migraine. J Intern Med 1992; 231: 551-4
27. Pfaffenrath V, Scherzer S. Analgesics and NSAIDs in the treatment of the acute migraine attack. Cephalalgia 1995; Suppl. 15: 14-20
28. Tfelt-Hansen P, Johnson ES. Nonsteroidal antiinflammatory drugs in the treatment of the acute migraine attack. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. New York: Raven Press Ltd, 1994: 305-11
29. Johnson ES, Tfelt-Hansen P. Nonsteroidal antiinflammatory drugs. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. New York: Raven Press Ltd, 1994: 391-5
30. Welch KMA, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology 1985; 35: 1304-10
31. Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 1990; 264: 1711-3
32. Silberstein SD, Lipton RB. Overview of diagnosis and treatment of migraine. Neurology 1994; 44 Suppl. 7: S6-16
33. Dalessio DJ. Caffeine as an analgesic adjuvant: review of the evidence. Headache 1994; Suppl. 1: 10-2
34. Silverman K, Evans SM, Strain EC, et al. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992; 327: 1109-14
35. MacGregor EA, Vohran C, Wilkinson M. Analgesic use: a study of treatments used by patients for migraine prior to attending The City of London Migraine Clinic. Headache 1990; 30: 571-4
36. Robinson RG. Pain relief for headaches: is self-medication a problem? Can Fam Physician 1993; 39: 867-72
37. Murphy JJ, Heptinstall S, Mitchell JRA. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988; 11 (8604): 189-92
38. Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 1994; 14; 328-9
39. Gobel H, Schmidt G, Soyka D. Effect of peppermint oil and eucalyptus oil preparations on neurophysiological and experimental algesimetric headache parameters. Cephalalgia. 1994; 14 (3): 228-34
40. Peikert A, Wilimzig C, Konne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16: 257-63
41. Pfaffenrath V, Wessely D, Meyer C, et al. Magnesium in the prophylaxis of migraine - a double-blind, placebo controlled study. Cephalalgia. In press
42. Stewart WF, Lipton RB. Migraine headache: epidemiology and health care utilization. Cephalalgia 1993; 13 Suppl. 12: 41-6
43. Salomone III JA, Thomas RW, Althoff JR, et al. An evaluation of the role of the ED in the management of migraine headaches. Am J Emerg Med 1994; 12: 134-7
44. Nichol MB, McCombs JS, Johnson KA. The effects of consultation on over-the-counter medication purchasing decisions. Med Care 1992; 30: 989-1003
45. Mathew NT. Chronic refractory headache. Neurology 1993; 43 Suppl. 3: S26-33
46. Welch KMA. Drug therapy of migraine. N Engl J Med 1993; 329 (20): 1476-83
47. Packard RC, O'Connell P. Medication compliance among headache patients. Headache 1986; 26: 416-9
48. Mathew NT. Drug-induced headache. In: Mathew NR, editor. Neurology clinics. Vol. 8. Philadelphia: WB Saunders Co. 1990; 8: 903-12
49. de Lissovoy G, Lazarus SS. The economic cost of migraine. Neurology 1994; 44 Suppl. 4: S56-62
50. Stewart WF, Lipton RB. The economic and social impact of migraine. Eur Neurol 1994; 34 Suppl. 2: 12-7
51. Stewart WF, Lipton RB. Societal impact of headache. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. New York: Raven Press Ltd, 1993: 29-34
52. Feste C, Anderson RM. Empowerment: from philosophy to practice. Patient Educ Couns 1995; 26: 139-44
53. Lipton RB, Stewart WF, Von Korff M. Migraine impact and functional disability. Cephalalgia 1995; Suppl. 15: 4-9
54. Lipton RB, Amatniek JC, Ferrari MD, et al. Migraine: identifying and removing barriers to care. Neurology 1994; Suppl. 4: S63-8